Press Releases Archives - Astrocyte Pharmaceuticals

Senator Chris Murphy Highlights Groton’s Astrocyte Pharmaceuticals As “Innovator Of The Month”

August 19, 2024 HARTFORD–U.S. Senator Chris Murphy (D-Conn.) on Monday announced that Astrocyte Pharmaceuticals, a Groton-based clinical-stage biopharmaceuticals company, was named “Innovator of the Month” for their work to advance cerebroprotective therapies for individuals suffering from stroke, traumatic brain injury (TBI), concussions and other neurodegenerative ailments. Stroke and TBI are among the leading causes of death […]

Senator Chris Murphy Highlights Groton’s Astrocyte Pharmaceuticals As “Innovator Of The Month” Read More »

Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004

Press Releases / korinek

Green Light for Phase 2 Trial of AST-004 in Acute Ischemic Stroke Patients Groton, CT, March 12, 2024 – Astrocyte Pharmaceuticals Inc., a clinical-stage biopharmaceutical company committed to advancing cerebroprotective therapies for individuals suffering from stroke, traumatic brain injury (TBI), and concussion, has announced today the U.S. Food and Drug Administration (FDA) has cleared the

Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004 Read More »

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M+ Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004

Press Releases / korinek

Groton, CT, August 18, 2023 – Astrocyte Pharmaceuticals Inc., a clinical-stage drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced an oversubscribed pre-Series B Bridge financing round of over $6M that was led by Dreavent Capital, and joined by the Alzheimer’s Drug Discovery Foundation, and other investors. The funding

Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M+ Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004 Read More »

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke

Press Releases / korinek

Groton, CT, April 10, 2023 – Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today announced that Theodore Liston, Ph.D., Vice President of Research at Astrocyte, received the 2022 Progress and Innovation Award from the journal Stroke for authoring one of the journal’s top three

Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke Read More »

Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries

Press Releases / korinek

Groton, CT, April 5, 2023 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, is pleased to announce the initiation of a Phase 1B study of its lead candidate, AST-004, as an extended infusion in healthy volunteers. This adaptive-design clinical study will be conducted over

Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries Read More »

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium

Press Releases / korinek

Groton, CT, September 14, 2022 – Astrocyte Pharmaceuticals Inc., a private drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, today provided an update on the preclinical and clinical development of its lead drug candidate, AST-004, in preclinical brain injury studies and in an ongoing clinical Phase 1 study. Theodore

Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium Read More »

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004

Press Releases / korinek

Groton, CT, June 15, 2022 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with brain injuries, announced that the Company’s first-in-human Phase 1 clinical study initiated today with the dosing of a first subject with AST-004. The promising investigational therapeutic, AST-004, is being advanced as a potential

Astrocyte Announces Initiation of First-In-Human Phase 1 Study of the Promising Stroke and Traumatic Brain Injury Therapeutic, AST-004 Read More »

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors

Press Releases / korinek

Groton, CT, December 14, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company developing novel cerebroprotective therapeutics for patients with brain injuries, announced today that Christine Gallagher has joined the company’s Board of Directors. Ms. Gallagher has over 30 years of experience as an investment banker focused on the life sciences industry. She

Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors Read More »

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic

Press Releases / korinek

Groton, CT, November 22, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate

Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic Read More »

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004

Press Releases / korinek

Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries, announced today the granting of a $3.0M award from the Medical Technology Enterprise Consortium (MTEC). The MTEC project award will support the upcoming Phase 1 human safety studies of

MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004 Read More »